CoChat

Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications

Open access
Lee Kennedy, R., Vangaveti, Venkat, Jarrod, Ghassan, Shashidhar, Venkatesh, Shashidhar, Venkatesh, Baune, Bernhard T. · 2010 · Therapeutic Advances in Endocrinology and Metabolism
Cited by 67

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Fatty acids (FAs) are important as metabolic substrates and as structural components of biological membranes. However, they also function as signalling molecules. Recently, a series of G protein-coupled receptors (GPRs) for FAs has been described and characterized. These receptors have differing specificities for FAs of differing chain length and degree of saturation, for FA derivatives such as oleoylethanolamide, and for oxidized FAs. They are a critical component of the body’s nutrient sensing apparatus, and small molecule agonists and antagonists of these receptors show considerable promise in the management of diabetes and its complications. Agonists of the long-chain free fatty acid receptors FFAR1 and GPR119 act as insulin secretagogues, both directly and by increasing incretins. Although, drugs acting at short-chain FFA receptors (FFAR2 and FFAR3) have not yet been developed, they are attractive targets as they regulate nutrient balance through effects in the intestine and adipose tissue. These include regulation of the secretion of cholecystokinin, peptide YY and leptin. Finally, GPR132 is a receptor for oxidized FAs, which may be a sensor of lipid overload and oxidative stress, and which is involved in atherosclerosis. Regulation of its signalling pathways with drugs may decrease the macrovascular risk experienced by diabetic patients. In summary, FA receptors are emerging drug targets that are involved in the regulation of nutrient status and carbohydrate tolerance, and modulators of these receptors may well figure prominently in the next generation of antidiabetic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2042018810381066

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 67

Metadata

Authors
Lee Kennedy, R., Vangaveti, V., Jarrod, G., Shashidhar, V., Shashidhar, V., & Baune, B. T.
Venue
Therapeutic Advances in Endocrinology and Metabolism
Published
2010-08-16
Volume
1
Issue
4
Pages
165-175
ISSN
  • 2042-0188 (ISSN-L)
  • 2042-0196
OpenAlex
W2104742442
Cited by
67
References
6
FWCI
1.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. https://app.cochat.ai/papers/10.1177/2042018810381066
The paper
Lee Kennedy, R., Vangaveti, V., Jarrod, G., Shashidhar, V., Shashidhar, V., & Baune, B. T. (2010). Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018810381066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.